Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various cancer conditions, growing popularity of advance therapies (biological and targeted drug therapies), patents expiration of leading drugs along with commercialization of biosimilars are the few factors driving the growth of global oncology drugs market

1. Published Date: 24 February 2015 No. of pages : 159
Global
Oncology/Cancer
Drugs Market
Forecast
2013 - 2020

2. Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for
treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various cancer
conditions, growing popularity of advance therapies (biological and targeted drug therapies), patents
expiration of leading drugs along with commercialization of biosimilars are the few factors driving the
growth of global oncology drugs market. However, high cost involved in new drug development
coupled with threat of failure and adverse effects associated with cancer drugs therapies would
restrain the growth of the market. Commercialization of advanced therapeutics such as targeted and
immunotherapies would reduce the negative influence of restraints and fuel the market growth.
The global oncology drugs market is expected to reach at $111.9 billion by 2020. Patent expiration of
key cancer drugs such as Herceptin, Erbitux, Rituxan and Avastin, is expected to boost the growth of
cancer biosimilars market by 2020. Going further, the biological therapies are expected to dominate
the market by 2020, due to their high efficacy, target specific action and less toxicity. Blood cancer
drugs market was the largest revenue generating segment in 2013 owing to the high cost of drugs
(immunotherapies) used for the treatment of blood cancer.
Geographically, North America, dominates the market followed by Europe. North America accounted
for about ~38% share in the overall oncology drugs market in 2013 owing to the heavy investments by
multinational companies in research and development of cancer drugs, particularly immune
therapeutics, favorable reimbursement policies, and high adoption rate of immunotherapies. On the
other hand, Asia-Pacific market would grow at the promising CAGR of 8.7% during the forecast period.
Introduction to Oncology/Cancer Drugs Market

3. Introduction
Scope of the Report
Key Benefits
Key Audiences

4. KEY BENEFITS
 The report provides the quantitative analysis of the current
market and estimations through 2013-2020 that assists in
identifying the prevailing market opportunities to capitalize on
 The report helps in understanding the strategies adopted by
various companies for gaining market share in the cancer drugs
market
 The report provides comprehensive analysis of factors that drive
and restrict the growth of the cancer drugs market
 Market conditions of cancer drugs market across all geographic
regions are comprehensively analysed
 Competitive intelligence (of leading manufacturers) helps in
understanding the competitive scenario across the geographies
 SWOT analysis of the key market players is provided to illustrate
the business strategies adopted by the companies

5. Table of Contents
1. INTRODUCTION
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
4. GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES
5. GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY CANCER TYPES
6. GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY GEOGRAPHY
7. COMPANY PROFILES

6. Global Oncology/Cancer Drugs Market
Overview
1. Market Definition & Scope
2. Development of novel immuno-oncology drug products
3. Key findings
4. Porter’s five forces analysis
5. Value chain analysis
6. Government regulations and reimbursement
7. Patent analysis
8. Market share analysis, 2013
9. Clinical trials for oncology drugs
10.Market dynamics

7. Global Oncology/Cancer Drugs Market By
Therapeutic Modalities
GLOBAL
ONCOLOGY/CAN
CER DRUGS
MARKET BY
THERAPEUTIC
MODALITIES
Chemotherapy
Targeted
therapy
Immunotherapy
(biologics
therapy)
Hormonal
therapy

8. Global Oncology/Cancer Drugs Market By
Cancer Types
GLOBAL
ONCOLOGY/CANCER
DRUGS MARKET BY
CANCER TYPES
Blood cancer
Breast cancer
Gastrointestinal cancer
Prostate cancer
Respiratory/lung cancer
Skin cancer

9. Global Oncology/Cancer Drugs Market By
Geography
North America, Europe, Asia Pacific, LAMEA

10. Company Profiles
1. Amgen Inc.
2. Johnson and Johnson
3. Roche Diagnostics
4. GlaxoSmithKline PLC
5. Merck & Company
6. Novartis AG
7. Pfizer
8. Sanofi
9. Eli Lilly and Company
10. Celgene Corporation

11. Follow Us On
Thank You!
For More Details
Visit us at
http://www.alliedmarketresearch.com/oncology-cancer-
drugs-market